RED® 72 SILVER LABEL is our latest large-bore Reperfusion Catheter, which provides the highest TRF on the marketa and is optimized for navigating challenging anatomy in LVO.

  • RED Reperfusion Catheters (RED 72 SILVER LABEL, RED 72 SILVER LABEL with SENDit® Technology, RED 68, and RED 62) are intended for use in the revascularization of patients with acute ischemic stroke. Every case is different, and the RED family of catheters provides a full range of products designed to optimize lumen size and trackability for the situation. All five products feature new REDglide™ Technology, which is designed to improve catheter interaction with vessels and to enhance delivery in tortuosity.

    • SILVER LABEL Technology: Blended transition zones designed for enhanced performance in challenging anatomy
    • .072″ (1.83 mm) Lumen: Delivers highest TRFa
    • .085″ (2.16 mm) Outer Diameter: Articulating marker band design to improve tip softness
    • REDglide Technology: Enhanced distal hydrophilic coating for smooth trackability
    • 132 cm Length: To reach target vessels

    a. As compared to AXS Vecta™ 71 and Stryker® (Medela), LBC and Vacuson 60, React™ 71 and Riptide™, AXS Vecta 74 and Stryker (Medela), and Zoom™ 71 and Zoom pump. Thrombus Removal Force (TRF) = (Catheter Tip Area) × (Vacuum). Sources: company website, marketing literature, IFU, and data on file.

    • Delivers and maintains nearly pure vacuum (-29.2 inHg or -98.88 kPa)b
    • Simple setup
    • Integrated clot catcher
    • Disposable Penumbra ENGINE® Canister
    • Compatible with all Penumbra System® Reperfusion Catheters

    b. Data on file at Penumbra, Inc.

The REDglide Difference

RED 72 vs JET 7

Resources

  • Document Icon

    In the News

    Read our latest news, articles, and posts.

  • Document Icon

    Meetings & Events

    View our conference and event schedule.

  • Document Icon

    Therapies & Conditions

    Learn more about how our products are used for a broad spectrum of conditions.

  • Document Icon

    Clinical Evidence

    Access the latest clinical research and data.

Questions?

Contact us to learn more about our products and company